NEW YORK (GenomeWeb) – Qiagen said today that it has acquired molecular oncology decision company N-of-One. Terms were not disclosed, but Qiagen said it made the purchase with cash reserves.

In purchasing Concord, Massachusetts-based N-of-One, Qiagen expects to beef up its offerings in decision support and offer its customers better clinical interpretation technologies for genomic data in pursuit of new, targeted therapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.